Opko Health’s ModeX presents results from Phase 1 study of SAR441236

ModeX Therapeutics, an OPKO Health company, announced results from a Phase 1 clinical study of SAR441236, its trispecific broadly neutralizing antibody against the human immunodeficiency virus, at the 2024 Conference on Retroviruses and Opportunistic Infections in Denver, Colorado. These clinical data are the first reported for a trispecific antibody and specifically provide support for the further development of multispecific, multivalent antibodies against HIV as a differentiated approach to addressing HIV infection. “This study represents a milestone in the development of multispecific antibodies, demonstrating key parameters of pharmacokinetics and safety. The study’s full data set inform our ongoing development of multispecific antibodies to prevent or treat HIV infection,” said Dr. John Mascola, Chief Scientific Officer of ModeX. “Existing oral antiretroviral therapies are a powerful tool in the fight against HIV, but multispecific antibodies offer long-lasting preventative and treatment options against a broad swathe of variants, with the possibility of activating the immune system against the latent virus population to effect a functional cure.”